Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion type Assertion NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_head.
- NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion wasGeneratedBy ECO_0000203 NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_provenance.
- NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion wasDerivedFrom befree-2016 NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_provenance.
- NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion SIO_000772 24679729 NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_provenance.
- NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion evidence source_evidence_literature NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_provenance.
- NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_assertion description "[The survival of patients with EGFR-mutant adenocarcinoma with BM is notably long, whether they receive upfront erlotinib or brain RT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1168424.RAUObwayBeXeWlGajyN7tI9loWgeCPDTqksfGhEmF-VX4130_provenance.